webdev, Author at Ispire Tech

Ispire Technology Expands Into High-Growth Nicotine Pouch Market Through Strategic Joint Venture with Jincheng Pharma

Partnership combines pharmaceutical-grade manufacturing with Ispire’s global platform to accelerate entry into one of the fastest-growing nicotine segments

LOS ANGELES, May 12, 2026 /PRNewswire/ — Ispire Technology Inc. (“Ispire” or the “Company”) (NASDAQ: ISPR), a trailblazer in vaping technology and precision dosing, announced that it has entered into a joint venture with Shandong Jincheng Pharmaceutical Group Co., Ltd. (SZSE: 300233) (“Jincheng Pharma”), a global pharmaceutical company, to manufacture and commercialize nicotine pouch products.

The joint venture marks Ispire’s entry into the rapidly expanding oral nicotine category, broadening its portfolio beyond vaping hardware and positioning the Company in one of the fastest-growing segments of the global nicotine market. According to Grand View Research, the nicotine pouch market was approximately $7 billion in 2025 and is projected to grow at nearly 25% annually through 2033, potentially exceeding $40 billion.

“This joint venture represents a meaningful strategic expansion for Ispire,” said Michael Wang, Co-Chief Executive Officer of Ispire. “Nicotine pouches are a major global growth category, and this partnership enables us to enter the market with immediate operational capability and pharmaceutical-grade manufacturing expertise. Combined with our global distribution and regulatory infrastructure, we believe this positions us to build a significant new revenue stream and further advance our broader nicotine platform strategy.”

Under the terms of the agreement, Jincheng Pharma will contribute manufacturing equipment, technical expertise, and nicotine pouch materials, enabling a rapid operational ramp-up and supporting near-term production and commercialization. The joint venture is expected to leverage Ispire’s strengths in precision dosing, regulatory compliance, and global distribution to differentiate its nicotine pouch offerings in an increasingly competitive market.

“Ispire’s proven manufacturing excellence and global regulatory capabilities accelerate our path to commercialization,” said Jiaquan Li, Chairman and President of Jincheng Pharma. “By combining our pharmaceutical expertise and customer relationships with Ispire’s operational capabilities, we are well positioned to scale high-quality nicotine pouch production quickly and responsibly.”

Jincheng Pharma is a diversified pharmaceutical company with approximately 3,800 employees and more than 30 affiliated companies worldwide. The company is engaged in the research, development, production, and commercialization of pharmaceutical intermediates, active pharmaceutical ingredients (APIs), finished pharmaceutical products, and health-related products.

Jincheng selected Ispire as its partner based on Ispire’s reputation for high-quality manufacturing, operational execution, and strong global regulatory compliance infrastructure.

The Company expects initial production to be supported by existing commercial relationships and intends to pursue additional business development opportunities within the oral nicotine segment as part of its broader international nicotine platform strategy.

This expansion builds on Ispire’s ongoing efforts to diversify its product portfolio across multiple reduced-risk nicotine formats while leveraging its manufacturing scale, compliance capabilities, and global distribution network.

About Ispire Technology Inc.
Ispire is engaged in the research and development, design, commercialization, sales, marketing and distribution of branded e-cigarettes and cannabis vaping products. The Company’s operating subsidiaries own or license more than 400 patents worldwide. Ispire’s branded e-cigarette products are marketed under the Aspire name and are sold worldwide (except in the U.S., People’s Republic of China and Russia) primarily through its global distribution network. The Company also engages in original design manufacture (ODM) relationships with e-cigarette brands and retailers worldwide. The Company’s cannabis products are marketed under the Ispire brand name primarily on an ODM basis to other cannabis vapor companies. Ispire sells its cannabis vaping hardware in the US, Europe and South Africa and it recently commenced marketing activities and customer engagement in Canada and Latin America. For more information, visit www.ispiretechnology.com or follow Ispire on Instagram, LinkedIn, Twitter and YouTube.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (“Securities Act”) as well as Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended, that are intended to be covered by the safe harbor created by those sections. Forward-looking statements, which are based on certain assumptions and describe the Company’s future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “would,” “could,” “seek,” “intend,” “plan,” “goal,” “project,” “estimate,” “anticipate,” “strategy,” “future,” “likely” or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the Company’s strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Important factors that could cause the Company’s actual results and financial condition to differ materially from those indicated in the forward-looking statements. Such forward-looking statements include, but are not limited to, risks and uncertainties including those regarding: whether the Company may be successful in re-entering the U.S. ENDS market; the approval or rejection of any PMTA submitted by the Company; whether the Company will be successful in its plans to further expand into the African market; whether the Company’s joint venture with Touch Point Worldwide Inc. d/b/a/ Berify and Chemular Inc. (the “Joint Venture”) may be successful in achieving its goals as currently contemplated, with different terms, or at all; the Joint Venture’s ability to innovate in the e-cigarette technology space or develop age gating or age verification technologies for nicotine vaping devices; the Company’s ability to collect its accounts receivable in a timely manner; the Company’s business strategies; the ability of the Company to market to the Ispire ONE™; Ispire ONE™’s success in meeting its goals; the ability of its customers to derive the anticipated benefits of the Ispire ONE™ and the success of its products on the markets; the Ispire ONE™ proving to be safe; and the risk and uncertainties described in “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” “Cautionary Note on Forward-Looking Statements” and the additional risk described in Ispire’s Annual Report on Form 10-K for the year ended June 30, 2025 and any subsequent filings which Ispire makes with the SEC. You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements made in this press release relate only to events or information as of the date on which the statements are made in this press release. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events except as required by applicable law. You should read this press release with the understanding that our actual future results may be materially different from what we expect.

IR Contact:
Brett Maas
Hayden IR
(646) 536-7331
brett@haydenir.com

James Carbonara
Hayden IR
(646)-755-7412
james@haydenir.com

PR Contact:
Ellen Mellody
+1-570-209-2947
ispire@kcsa.com

SOURCE Ispire Technology Inc.

May 12, 2026

Ispire Technology Inc. Reports Financial Results for Fiscal Third Quarter 2026

Cash Increased Sequentially by $468,000 to $18 Million

Plans to Achieve Cash Flow Positive in Second Half of Calendar Year 2026

Business Stabilized Following Strategic Repositioning

Phased Roadmap Targets Billions in Addressable Market, Including ~$73B Global Vape, ~$50–70B U.S. Flavored Vape, and $24B+ Global G-Mesh Glass Technology

LOS ANGELES, May 7, 2026 /PRNewswire/ — Ispire Technology Inc. (Nasdaq: ISPR) (“Ispire,” the “Company,” “we,” “us,” or “our”), an innovator in vaping technology and precision dosing, today reported financial results for the third quarter of fiscal 2026, for the three months ended March 31, 2026.

Michael Wang, Co-Chief Executive Officer of Ispire, commented, “This quarter reflects the successful stabilization of our business and with cash growing sequentially by $468,000 to $18 million, we are now executing against a phased roadmap, with near-term revenue drivers already in production and transformative technology opportunities on the horizon:

Our Malaysia manufacturing is live today, giving us a 25% tariff advantage over China in a ~$73B global vape market.
Supply of nicotine pouches to global customers commenced in April 2026.
Vapor ODM launches in July 2026 for mid-sized brands, with large brand partnerships targeted for 2027.
Looking further ahead (2027 and beyond):
Age-gating technology through IKE Tech has the potential to unlock the ~$50–70B US flavored vape market
G-Mesh glass technology is already drawing interest from big tobacco in a $24B+ legal global market.
“With cash generation this quarter and proprietary technologies in age-gating and G-Mesh that no competitor can replicate, we have multiple shots on goal across billion-dollar markets, and we believe Ispire is uniquely positioned to deliver outsized value for shareholders.”

Multiple Growth Catalysts, Each Backed by a Massive Addressable Market

Catalyst	Timeline	Opportunity
Malaysia Manufacturing	Now	~$73B global vape market; 25% tariff advantage over China
Vapor ODM	July 2026 / 2027	Mid-sized brands in 2026; large brand partnerships in 2027
Age-Gating (IKE Tech)	2027+	~$50-70B US flavored vape market currently locked; ~6B devices/year US TAM
G-Mesh Technology	2027+	$24B+ legal global vape market; licensing discussions with big tobacco underway

Financial Results for the Fiscal Third Quarter Ended March 31, 2026

Revenue was $18.7 million, compared to $26.2 million in the third quarter of fiscal 2025 and $20.3 million in the prior sequential quarter. The sequential decline of $1.6 million, or 8%, represents the smallest second-to-third quarter decline in the Company’s history, reflecting the typical seasonal impact of Chinese New Year-related factory shutdowns. The year-over-year decline reflects the Company’s continued strategic shift away from lower-quality cannabis revenue toward regulated nicotine delivery and compliance technologies. Overall, the business continues to stabilize.
Gross profit of $2.0 million compared to $4.8 million for the third quarter of fiscal 2025 and $3.5 million in the prior sequential quarter. Gross margin was impacted by approximately $2.2 million in one-time product returns from legacy cannabis customers with whom the Company has ceased doing business. Gross margin of 10.7% compared to 18.2% for the third quarter of fiscal 2025, is primarily attributable to the approximately $2.2 million one-time product returns from legacy cannabis customers with whom the Company has ceased doing business.
Total operating expenses excluding bad debt expense of $5.9 million, a 36% reduction when compared to operating expenses of $9.3 million for the third quarter of fiscal 2025, and a 3.7% reduction when compared to operating expenses of $6.1 million in the prior sequential quarter. Bad debt expense was $5.6 million, which is $0.5 million less than the third quarter of fiscal 2025 and $1.4 million more than the prior quarter.
Net loss of $9.5 million or ($0.17) per share, a 12.3% decrease, compared to net loss of $10.9 million, or ($0.19) per share, in the third quarter of fiscal 2025, and a 44.4% increase compared a net loss of $6.6 million in the prior sequential quarter.
Cash: At March 31, 2026, the Company held cash of $18.0 million and working capital of $0.9 million.

Conference Call

The Company will conduct a conference call at 8 am ET on Friday, May 7, 2026, to discuss the results, followed by a Q&A session.

To listen to the conference call, please dial in using the information below. When prompted upon dialing-in, please ask for the “Ispire Technology Call.”

Date: Thursday, May 7, 2026
Time: 8:00 am ET
Dial-In Numbers: United States 844-826-3033 or International + 1-412-317-5185

This conference call will be webcast live and can be accessed by all interested parties at https://viavid.webcasts.com/starthere.jsp?ei=1761477&tp_key=3958311007

Please access the link at least fifteen minutes prior to the start of the call to register, download, and install any necessary audio software.

A playback will be available until 11:59 pm ET on Friday, May 21, 2026. To listen, please dial 1-844-512-2921 or 1-412-317-6671. Use the passcode 10208863 to access the replay.

About Ispire Technology Inc.

Ispire is engaged in the research and development, design, commercialization, sales, marketing and distribution of branded e-cigarettes and cannabis vaping products. The Company’s operating subsidiaries own or license more than 400 patents worldwide. Ispire’s branded e-cigarette products are marketed under the Aspire name and are sold worldwide (except in the U.S., People’s Republic of China and Russia) primarily through its global distribution network. The Company also engages in original design manufacture (ODM) relationships with e-cigarette brands and retailers worldwide. The Company’s cannabis products are marketed under the Ispire brand name primarily on an ODM basis to other cannabis vapor companies. Ispire sells its cannabis vaping hardware in the US, Europe and South Africa and it recently commenced marketing activities and customer engagement in Canada and Latin America. For more information visit www.ispiretechnology.com or follow Inspire on Instagram, LinkedIn, Twitter and YouTube.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (“Securities Act”) as well as Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended, that are intended to be covered by the safe harbor created by those sections. Forward-looking statements, which are based on certain assumptions and describe the Company’s future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “would,” “could,” “seek,” “intend,” “plan,” “goal,” “project,” “estimate,” “anticipate,” “strategy,” “future,” “likely” or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the Company’s strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Important factors that could cause the Company’s actual results and financial condition to differ materially from those indicated in the forward-looking statements. Such forward-looking statements include, but are not limited to, risks and uncertainties including those regarding: whether the Company may be successful in re-entering the U.S. ENDS market; the approval or rejection of any PMTA submitted by the Company; whether the Company will be successful in its plans to further expand into the African market; whether the Company’s joint venture with Touch Point Worldwide Inc. d/b/a/ Berify and Chemular Inc. (the “Joint Venture”) may be successful in achieving its goals as currently contemplated, with different terms, or at all; the Joint Venture’s ability to innovate in the e-cigarette technology space or develop age gating or age verification technologies for nicotine vaping devices; the Company’s ability to collect its accounts receivable in a timely manner; the Company’s business strategies; the ability of the Company to market to the Ispire ONE™; Ispire ONE™’s success in meeting its goals; the ability of its customers to derive the anticipated benefits of the Ispire ONE™ and the success of its products on the markets; the Ispire ONE™ proving to be safe; and the risk and uncertainties described in “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” “Cautionary Note on Forward-Looking Statements” and the additional risk described in Ispire’s Annual Report on Form 10-K for the year ended June 30, 2025 and any subsequent filings which Ispire makes with the SEC. You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements made in this press release relate only to events or information as of the date on which the statements are made in this press release. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events except as required by applicable law. You should read this press release with the understanding that our actual future results may be materially different from what we expect.

Contact:

HAYDEN IR:
James Carbonara
(646)-755-7412
james@haydenir.com

Brett Maas
(646) 536-7331
brett@haydenir.com

— Tables Follow –

ISPIRE TECHNOLOGY INC. UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (In $USD, except share and per share data)

	March 31, 2026		June 30, 2025
Assets
Current assets:
Cash	$	18,033,652	$	24,351,765
Restricted cash		50,000		–
Accounts receivable, net		28,651,558		39,664,145
Inventories		5,480,044		6,647,970
Prepaid expenses and other current assets		3,523,741		2,244,505
Total current assets		55,738,995		72,908,385
Non-current assets:
Accounts receivable, net of current portion		–		7,367,158
Property, plant and equipment, net		2,665,534		2,952,800
Intangible assets, net		2,601,408		2,232,620
Right-of-use assets – operating leases		3,855,373		5,030,005
Other investment		2,000,000		2,000,000
Equity method investment		8,839,130		9,515,546
Other non-current assets		210,617		210,617
Total non-current assets		20,172,062		29,308,746
Total assets	$	75,911,057	$	102,217,131
Liabilities and stockholders’ (deficit)/equity
Current liabilities
Accounts payable	$	5,005,033	$	4,172,476
Accounts payable – related party		38,159,288		52,420,256
Contract liabilities		3,043,470		4,861,250
Accrued liabilities and other payables		6,003,509		8,099,991
Borrowing – current portion		1,092,052		1,146,766
Operating lease liabilities – current portion		1,546,770		1,838,815
Total current liabilities		54,850,122		72,539,554

Non-current liabilities:
Amount due to a related party		35,000,000		25,000,000
Borrowing – net of current portion		–		805,361
Operating lease liabilities – net of current portion		2,265,347		3,267,522
Total non-current liabilities		37,265,347		29,072,883
Total liabilities		92,115,469		101,612,437

Commitments and contingencies

Stockholders’ (deficit)/equity:
Common stock, par value $0.0001 per share; 140,000,000 shares authorized; 57,399,396 and 57,193,734 shares issued and outstanding as of March 31, 2026 and June 30, 2025		5,740		5,719
Treasury stock, at cost		(60,488)		(60,488)
Additional paid-in capital		51,541,046		48,833,601
Accumulated deficit		(67,450,024)		(48,065,267)
Accumulated other comprehensive loss		(240,686)		(108,871)
Total stockholders’ (deficit)/equity		(16,204,412)		604,694
Total liabilities and stockholders’ (deficit)/equity	$	75,911,057	$	102,217,131

ISPIRE TECHNOLOGY INC. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (In $USD, except share and per share data)

	Three Months Ended March 31,				Nine Months Ended March 31,
	2026		2025		2026		2025

Revenue	$	18,685,501	$	26,190,725	$	69,322,941	$	107,356,898

Cost of revenue		16,694,576		21,414,820		58,710,643		87,184,044

Gross profit		1,990,925		4,775,905		10,612,298		20,172,854

Operating expenses:
Sales and marketing expenses		1,091,907		1,656,527		4,133,079		6,710,438
Credit loss expenses		5,564,497		6,103,688		11,537,950		13,389,767
General and administrative expenses		4,818,256		7,601,131		13,995,180		23,281,014

Total Operating expenses		11,474,660		15,361,346		29,666,209		43,381,219

Loss from operations		(9,483,735)		(10,585,441)		(19,053,911)		(23,208,365)

Other income (expense):
Interest income		52,971		3,480		253,365		63,321
Interest expense		(87,215)		(35,646)		(299,582)		(60,183)
Exchange (loss) gain, net		(30,294)		24,341		269,745		(103,247)
Other income (expense), net		202,697		(86,239)		215,688		(47,906)

Total Other income (expense), net		138,159		(94,064)		439,216		(148,015)

Loss before income taxes		(9,345,576)		(10,679,505)		(18,614,695)		(23,356,380)

Income taxes		(177,407)		(176,990)		(770,062)		(1,093,774)

Net loss	$	(9,522,983)	$	(10,856,495)	$	(19,384,757)	$	(24,450,154)

Other comprehensive loss
Foreign currency translation adjustments		(10,490)		(2,860)		(131,815)		(84,327)
Comprehensive loss	$	(9,533,473)	$	(10,859,355)	$	(19,516,572)	$	(24,534,481)

Net loss per share
Basic and diluted	$	(0.17)	$	(0.19)	$	(0.34)	$	(0.43)

Weighted average shares outstanding:
Basic and diluted		57,293,826		57,003,488		57,269,726		56,752,454

ISPIRE TECHNOLOGY INC. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (In $USD, except share and per share data)

	Nine Months Ended March 31,
	2026		2025

Net loss	$	(19,384,757)	$	(24,450,154)
Adjustments to reconcile net loss to net cash (used in)/provided by operating activities:
Depreciation and amortization		691,894		592,280
Credit loss expenses		11,537,950		13,389,767
Right-of-use assets amortization		1,172,118		1,001,101
Stock-based compensation expenses		2,752,467		4,923,751
Inventory impairment		2,386,751		73,692
Loss from equity method investment		676,416		407,028
Debt issuance cost amortization		96,937		–
Changes in operating assets and liabilities:
Accounts receivable		6,841,795		(14,080,837)
Inventories		(1,218,825)		(1,485,433)
Prepaid expenses and other current assets		(1,332,448)		(715,969)
Accounts payable and accounts payable – related party		(3,428,411)		10,962,439
Contract liabilities		(1,817,780)		(756,872)
Accrued liabilities and other payables		(876,774)		(969,068)
Operating lease liabilities		(1,291,706)		(961,244)
Net cash used in operating activities		(3,194,373)		(12,069,519)

Cash flows from investing activities:
Purchase of property, plant and equipment		(324,225)		(140,956)
Capitalized costs for patents		(449,191)		(781,254)
Investment in joint venture		(1,298,311)		(767,285)
Net cash used in investing activities		(2,071,727)		(1,689,495)

Cash flows from financing activities:
Common stock repurchase		(45,001)		(60,488)
Proceeds from long term debt		–		2,339,362
Repayment of borrowing		(957,012)		–
Net cash (used in)/provided by financing activities		(1,002,013)		2,278,874

Net decrease in cash		(6,268,113)		(11,480,140)
Cash – beginning of period		24,351,765		35,071,294
Cash and restricted cash– end of period	$	18,083,652	$	23,591,154
Reconciliation of cash and restricted cash
Cash		18,033,652		23,518,560
Restricted cash		50,000		72,594
Total cash and restricted cash	$	18,083,652	$	23,591,154
Supplemental non-cash investing and financing activities
Reclassification of accounts receivable – noncurrent to accounts receivable	$	6,934,364	$	–
Reclassification of accounts payable – related party to amount due to a related party	$	10,000,000	$	–
Leased assets obtained in exchange for operating lease liabilities	$	–	$	2,771,082
Unpaid long term investment in accrued liabilities and other payables	$	–	$	8,232,715
Supplemental disclosures
Cash paid for income taxes	$	1,614,273	$	1,413,533
Cash paid for interest	$	299,582	$	60,183

ISPIRE TECHNOLOGY INC. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (In $USD, except share and per share data)

	Three Months Ended
	March 31,
	2026	2025
Net loss	$ (9,522,983)	$ (10,856,495)
Adjustments to reconcile net loss to net cash -used in/ provided by operating activities:	$ –	$ –
Depreciation and amortization	$ 210,652	$ 198,955
Credit loss expenses	$ 5,564,497	$ 6,103,688
Right-of-use assets amortization	$ 479,982	$ 371,717
Stock-based compensation expenses	$ 992,478	$ 1,470,877
Inventory impairment	$ 849,313	$ –
Loss from equity method investment	$ 290,083	$ 230,360
Debt issuance cost amortization	$ 32,312	$ –
Changes in operating assets and liabilities:	$ –	$ –
Accounts receivable	$ 3,662,298	$ 1,170,940
Inventories	$ (1,291,943)	$ 181,075
Prepaid expenses and other current assets	$ (363,641)	$ 139,686
Accounts payable and accounts payable – related party	$ 3,582,462	$ (9,743,313)
Contract liabilities	$ (1,927,665)	$ (549,992)
Accrued liabilities and other payables	$ (99,500)	$ (838,174)
Operating lease liabilities	$ (489,737)	$ (376,953)
Income tax payable	$ (12,590)	$ –
Net cash provided by operating activities	$ 1,956,018	$ (12,497,629)
	$ –
Cash flows from investing activities:	$ –
Purchase of property, plant and equipment	$ (247,347)	$ 181,808
Capitalized costs for patents	$ (156,349)	$ –
Investment in joint venture	$ (765,000)	$ (767,285)
Net cash used in investing activities	$ (1,168,696)	$ (585,477)
	$ –
Cash flows from financing activities:	$ –
Common stock repurchase	$ –	$ (60,488)
Proceeds from long term debt	$ –	$ 2,339,362
Repayment of borrowing	$ (319,004)	$ –
Net cash used in financing activities	$ (319,004)	$ 2,278,874
	$ –
Net increase in cash	$ 468,318	$ (10,804,232)
Cash – beginning of period	$ 17,615,334	$ 34,395,386
Cash and restricted cash– end of period	$ 18,083,652	$ 23,591,154
Reconciliation of cash and restricted cash
Cash	$ 18,033,652	$ 23,518,560
Restricted cash	$ 50,000	$ 72,594
Total cash and restricted cash	$ 18,083,652	$ 23,591,154
Supplemental non-cash investing and financing activities
Reclassification of accounts receivable – noncurrent to accounts receivable	$ –	$ –
Reclassification of accounts payable – related party to amount due to a related party	$ 6,000,000	$ –
Leased assets obtained in exchange for operating lease liabilities	$ –	$ 2,771,082
Unpaid long term investment in accrued liabilities and other payables	$ –	$ 8,232,715
Supplemental disclosures	$ –	$ –
Cash paid for income taxes	$ 3,081 –	$ –
Cash paid for interest	$ 87,215	$ 35,646

SOURCE Ispire Technology Inc.

May 7, 2026

Ispire Technology Inc. Schedules Fiscal Third Quarter 2026 Earnings Conference Call

LOS ANGELES, May 1, 2026 /PRNewswire/ — Ispire Technology Inc. (“Ispire” or the “Company”) (NASDAQ: ISPR), a trailblazer in vaping technology and precision dosing, announced today that it will host its earnings conference call at 8:00 am ET on Thursday, May 7, 2026, to discuss the Company’s financial results for its fiscal third quarter ended March 31, 2026.

To listen to the conference call, please dial in using the information below. When prompted upon dialing-in, please ask for the “Ispire Technology Call.”

Date: Thursday, May 7, 2026
Time: 8:00 am ET
Dial-In Numbers: United States 844-826-3033 or International + 1-412-317-5185

This conference call will be webcast live and can be accessed by all interested parties at https://viavid.webcasts.com/starthere.jsp?ei=1761477&tp_key=3958311007

Please access the link at least fifteen minutes prior to the start of the call to register, download, and install any necessary audio software.

A playback will be available until 11:59 pm ET on Friday, May 21, 2026. To listen, please dial 1-844-512-2921 or 1-412-317-6671. Use the passcode 10208863 to access the replay.

About Ispire Technology Inc.
Ispire is engaged in the research and development, design, commercialization, sales, marketing and distribution of branded e-cigarettes and cannabis vaping products. The Company’s operating subsidiaries own or license more than 400 patents worldwide. Ispire’s branded e-cigarette products are marketed under the Aspire name and are sold worldwide (except in the U.S., People’s Republic of China and Russia) primarily through its global distribution network. The Company also engages in original design manufacture (ODM) relationships with e-cigarette brands and retailers worldwide. The Company’s cannabis products are marketed under the Ispire brand name primarily on an ODM basis to other cannabis vapor companies. Ispire sells its cannabis vaping hardware in the US, Europe and South Africa and it recently commenced marketing activities and customer engagement in Canada and Latin America. For more information, visit www.ispiretechnology.com or follow Ispire on Instagram, LinkedIn, Twitter and YouTube.

Investor Contacts:

Brett Maas
Hayden IR
(646) 536-7331
brett@haydenir.com

James Carbonara
Hayden IR
(646)-755-7412
james@haydenir.com

SOURCE Ispire Technology Inc.

May 1, 2026

Ispire Highlights Economic Impact of New FDA Guidance on Flavored ENDS Unlocking a $50 Billion Market and Driving Significant Potential Asset Value

FDA establishes first-ever framework for flavored ENDS, recognizing device level age verification as a regulatory requirement

FDA guidance unlocks an estimated $50 billion total addressable market, allowing companies to lawfully transition the 70% illicit flavored vape market into a compliant ecosystem

Ispire’s 40%-owned IKE Tech joint venture is positioned to generate $5 million to $20 million in annual recurring SaaS revenue per customer in the US

Based on conservative SaaS metrics, even a limited number of customers could potentially value the IKE joint venture in the hundreds of millions, dramatically increasing Ispire’s book value

Ispire-backed IKE Tech was first to file component PMTA for continuous, blockchain-enabled age-gating technology
LOS ANGELES, March 16, 2026 /PRNewswire/ — Ispire Technology Inc. (“Ispire” or the “Company”) (NASDAQ: ISPR), a trailblazer in vaping technology and precision dosing, today highlighted the massive economic value and multi-billion-dollar market opportunity created for its shareholders by the U.S. Food and Drug Administration’s (FDA) newly issued draft guidance outlining evidentiary expectations for Premarket Tobacco Product Applications (PMTAs) for flavored electronic nicotine delivery systems (ENDS).

The FDA’s guidance effectively unlocks a $50 billion total addressable market by providing a lawful pathway for flavored vapes, which currently consist largely of illicit products. Ispire’s 40%-owned joint venture, IKE Tech LLC (“IKE Tech” or “IKE”), is uniquely positioned to capture this market. IKE’s recurring SaaS revenue model is expected to generate $5 million to $20 million annually per customer. Management believes that securing even a limited number of customers could value the IKE joint venture in the hundreds of millions, creating a highly valuable asset on Ispire’s balance sheet.

The guidance marks the first time the FDA has formally outlined a framework for evaluating flavored ENDS products, recognizing that device-level access technologies — or Device Access Restrictions (DAR) — may factor into whether a product meets the “appropriate for the protection of public health” (APPH) standard for PMTA authorization.

The draft guidance highlights DAR technologies such as biometric authentication, geofencing, and continuous age verification as potential safeguards designed to prevent underage use of ENDS devices. FDA also emphasizes that traditional safeguards such as local age restrictions and point-of-sale verification that do not directly prevent youth use may not, when employed alone, sufficiently reduce youth use.

“We believe this guidance represents a major step toward a technology-enabled regulatory framework for the vapor category,” said Michael Wang, Co-Chief Executive Officer of Ispire. “FDA’s recognition of Device Access Restrictions validates our long-held position that continuous, device-level age verification can protect youth while preserving adult choice.”

Ispire has long advocated for technology-driven youth prevention solutions. Through IKE, a joint venture that includes Ispire as a founding partner, the Company has supported the development of advanced identity and authentication systems designed to control device access directly at the point of use, rather than solely at the point of sale.

In 2025, IKE Tech submitted the first-ever component PMTA for a standalone, interoperable age-verification technology designed for integration across ENDS devices. The platform combines Bluetooth Low Energy (BLE) chips, biometric authentication, and blockchain-secured identity verification to ensure that only verified adult users can activate a device. In a multi-center Human Factors Validation Study submitted with the PMTA, the IKE age-gating technology achieved:

100% effectiveness in preventing device activation by underage users
100% accuracy in demographic verification
User error rates below 1%, underscoring ease of use for adults
91% user satisfaction with app simplicity and functionality
In addition to age verification, the IKE technology platform can also support product authentication and anti-counterfeiting capabilities, helping manufacturers and regulators identify illicit or counterfeit devices that bypass regulatory safeguards, evade taxes, and undermine consumer safety.

Economic Opportunity and Market Impact

The FDA’s draft guidance may immediately unlock access to a multi-billion-dollar segment of the U.S. vapor market. With flavored products representing a substantial portion of consumer demand, the agency’s recognition of DAR creates a potential pathway for compliant manufacturers to compete in segments previously dominated by illicit trade.

Industry estimates suggest that approximately 70% of the current U.S. vape market consists of illicit or unauthorized products. Data suggests that the total U.S. vapor market is currently around $50 billion annually, when accounting for hard-to-track illicit and unauthorized products. IKE’s technological solutions will allow companies to address this massive total market.

Over recent months, IKE Tech is actively working with large tobacco companies, leading independent brands, and several of the largest e-cigarette manufacturers to evaluate integration of its technology into flavored PMTA submissions, while also receiving strong inbound interest from manufacturers seeking to bring compliant flavored ENDS products to the U.S. market.

Following the FDA’s guidance, Ispire believes this framework could also influence global regulatory policy, with several major markets potentially moving toward mandating device-level age verification for ENDS products.

IKE’s business model is structured as a recurring compliance technology platform, generating SaaS revenue from manufacturers integrating the system into their devices. Each customer using the technology is expected to generate approximately $5 million – $20 million in annual recurring SaaS revenue, alongside recurring per-device hardware sales or firmware licensing fees. Even a limited number of authorized flavored ENDS products incorporating IKE’s technology could create significant enterprise value for the platform.

About IKE Tech LLC

IKE Tech LLC is a joint venture comprised of Ispire Technology Inc., Touch Point Worldwide Inc. d/b/a Berify, and Chemular Inc. Founded in 2024, IKE Tech is building the identity layer for the physical world. With patented technologies spanning blockchain authentication, secure BLE communication, and AI-enhanced access control, IKE powers secure, user-centric device interactions across regulated and high-risk sectors.

IKE’s System-on-a-Chip allows manufacturers to embed customizable, interoperable access controls into vapor devices — ensuring authorized adult use and preventing youth access through real-time mobile and biometric authentication. Visit www.iketech.com.

About Ispire Technology Inc.

Ispire is engaged in the research and development, design, commercialization, sales, marketing and distribution of branded e-cigarettes and cannabis vaping products. The Company’s operating subsidiaries own or license more than 400 patents worldwide. Ispire’s branded e-cigarette products are marketed under the Aspire name and are sold worldwide (except in the U.S., People’s Republic of China and Russia) primarily through its global distribution network. The Company also engages in original design manufacture (ODM) relationships with e-cigarette brands and retailers worldwide. The Company’s cannabis products are marketed under the Ispire brand name primarily on an ODM basis to other cannabis vapor companies. Ispire sells its cannabis vaping hardware in the US, Europe and South Africa and it recently commenced marketing activities and customer engagement in Canada and Latin America. For more information, visit www.ispiretechnology.com or follow Ispire on Instagram, LinkedIn, Twitter and YouTube.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (“Securities Act”) as well as Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended, that are intended to be covered by the safe harbor created by those sections. Forward-looking statements, which are based on certain assumptions and describe the Company’s future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “would,” “could,” “seek,” “intend,” “plan,” “goal,” “project,” “estimate,” “anticipate,” “strategy,” “future,” “likely” or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the Company’s strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Important factors that could cause the Company’s actual results and financial condition to differ materially from those indicated in the forward-looking statements. Such forward-looking statements include, but are not limited to, risks and uncertainties including those regarding: whether the Company may be successful in re-entering the U.S. ENDS market; the approval or rejection of any PMTA submitted by the Company; whether the Company will be successful in its plans to further expand into the African market; whether the Company’s joint venture with Touch Point Worldwide Inc. d/b/a/ Berify and Chemular Inc. (the “Joint Venture”) may be successful in achieving its goals as currently contemplated, with different terms, or at all; the Joint Venture’s ability to innovate in the e-cigarette technology space or develop age gating or age verification technologies for nicotine vaping devices; the Company’s ability to collect its accounts receivable in a timely manner; the Company’s business strategies; the ability of the Company to market to the Ispire ONE™; Ispire ONE™’s success in meeting its goals; the ability of its customers to derive the anticipated benefits of the Ispire ONE™ and the success of its products on the markets; the Ispire ONE™ proving to be safe; and the risk and uncertainties described in “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” “Cautionary Note on Forward-Looking Statements” and the additional risk described in Ispire’s Annual Report on Form 10-K for the year ended June 30, 2025 and any subsequent filings which Ispire makes with the SEC. You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements made in this press release relate only to events or information as of the date on which the statements are made in this press release. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events except as required by applicable law. You should read this press release with the understanding that our actual future results may be materially different from what we expect.

IR Contact:
Phil Carlson
+1-212-896-1233
ispire@kcsa.com

PR Contact:
Ellen Mellody
+1-570-209-2947
ispire@kcsa.com

SOURCE Ispire Technology Inc.

March 16, 2026

Ispire Technology Inc. to Participate in the 38th Annual ROTH Conference

Los Angeles, March 11, 2026 – Ispire Technology Inc. (NASDAQ: ISPR) (“Ispire,” the “Company,” “we,” “us,” or “our”), an innovator in vaping technology and precision dosing, today announced that Ispire’s management team will participate in the 38th Annual ROTH Conference taking place in Dana Point, California from March 22-24, 2026.

38th Annual ROTH Conference
Date: March 22-24, 2026
Location: Dana Point, California
Fireside Chat Details: Monday, March 23, 2026, at 8:00 a.m. PT in Blue-Consumer-Salon 2

To schedule a one-on-one meeting with the Company’s management team, please contact your representative at ROTH, or email KCSA Strategic Communications at Ispire@KCSA.com.

About Ispire Technology Inc.
Ispire is engaged in the research and development, design, commercialization, sales, marketing, and distribution of branded e-cigarettes and cannabis vaping products. The Company’s operating subsidiaries own or license more than 200 patents received or filed globally. Ispire’s tobacco products are marketed under the Aspire brand name and are sold worldwide (except in the U.S., People’s Republic of China and Russia) primarily through its global distribution network. The Company’s cannabis products are marketed under the Ispire brand name primarily on an original design manufacturer (ODM) basis to other cannabis vapor companies. Ispire sells its cannabis vaping hardware only in the U.S., and it recently commenced its marketing activities in Canada and Europe. For more information, visit www.ispiretechnology.com or follow Ispire on Instagram, LinkedIn, Twitter and YouTube. Any information contained on, or that can be accessed through, the Company’s website, any other website or any social media, is not a part of this press release.

For more information, kindly contact:

IR Contacts:
Investor Relations
KCSA Strategic Communications
Phil Carlson
212-896-1233
ispire@kcsa.com

PR Contact:
Ellen Mellody
570-209-2947
EMellody@kcsa.com

March 11, 2026

Ispire Technology Inc. Reports Financial Results for Fiscal Second Quarter 2026

Ongoing Focus on Collections Drives 19% Reduction in Net Accounts Receivable since June 30, 2025

Cash of $17.6 Million at December 31, 2025

Los Angeles, February 6, 2026 – Ispire Technology Inc. (NASDAQ: ISPR) (“Ispire,” the “Company,” “we,” “us,” or “our”), an innovator in vaping technology and precision dosing, today reported financial results for the second quarter of fiscal 2026, for the three months ended December 31, 2025.

Fiscal Second Quarter 2026 Financial Results

Revenue of $20.3 million versus $41.8 million for the second quarter of fiscal 2025.
Gross profit of $3.5 million compared to $7.7 million for the second quarter of fiscal 2025.
Gross margin of 17.1% compared to 18.5% for the second quarter of fiscal 2025.
Total operating expenses of $10.3 million compared to $15.1 million for the second quarter of fiscal 2025.
Net loss of $6.6 million, compared to net loss of $8.0 million in the second quarter of fiscal 2025.

“This quarter represented an inflection point for Ispire during its yearlong cost cutting and customer quality rationalization efforts and we believe future quarters will see top line growth, consistent cash flows and bottom-line improvement. We are confident we have laid a solid foundation for future success,” commented Michael Wang, Co-Chief Executive Officer of Ispire. “During the second quarter of fiscal 2026, we maintained our focus on prioritizing high-quality revenue, and reinforcing our disciplined and intentional approach to sustainable growth. This was particularly evident in our efforts to reduce net accounts receivable, which continues to have strong success. Over the second fiscal quarter we reduced net accounts receivable by 19.5% to $37.9 million, compared to $47.0 million at the end of fiscal year 2025.”

“We continue to lay important groundwork across core areas of the business, including the ramp up of our manufacturing capabilities in Malaysia as we prepare to increase production throughout fiscal 2026. Momentum continues to build for our proprietary G-Mesh technology, with several large and mid-sized nicotine manufacturers engaged in discussions to evaluate its use in next-generation vaping devices, as we work toward potential licensing and partnership opportunities. In addition, our IKE Tech joint venture is making steady global progress, collaborating with regulators across Europe, Southeast Asia, and the Middle East to support the broader adoption of age-gating technology as a safer industry standard. In the US, although most adult consumers want flavored e-cigarettes, nearly all of the flavored e-cigarettes are both unauthorized by the FDA and sold through illicit channels. While we welcome the US Federal Government’s strengthened enforcement mandate of the illicit trade of vapes, we believe that such enforcement can only be truly effective by pairing it with the creation of a robust, legal market of FDA authorized flavored e-cigarette products. Ispire, with IKE, is a key player in the creation of this market of legal, approved products, using its technologies to both prevent youth-access, ensure product authenticity and provide solutions to secure devices before misuse occurs. This is where we are seeing macro tailwinds in our favor relating to the US FDA’s stated position on flavored ENDS products and age-gating. Since October 2025, the FDA’s explicit position is that you must have age gating technology if you want flavored products approved. Ispire, through its IKE joint venture, has one of the leading and most low friction technologies in this space, and we look forward to capitalizing on this opportunity in due time”, Mr. Wang concluded.

Jay Yu, Chief Financial Officer of Ispire, said, “The second quarter of fiscal 2026 reflects continued progress as we focused on strengthening the Company’s financial foundation. Disciplined cost controls drove a year-over-year decline in operating expenses, which decreased from $15.1 million to $10.3 million over the second fiscal quarter, highlighting the impact of our efficiency initiatives. Our net accounts receivable also declined to $37.9 million as of December 31, 2025, compared with $47.0 million as of June 30, 2025, reflecting our ongoing focus on higher-quality customers. These actions position the Company for enhanced financial flexibility and support sustained value creation over the long term.”

Financial Results for the Fiscal Second Quarter Ended December 31, 2025

Ispire reported revenue of $20.3 million for the fiscal second quarter ended December 31, 2025, versus $41.8 million for the prior comparable period. The decrease in revenue is due to the strategic shift away from lower quality cannabis customers, resulting in a decrease of overall product sales.

For the second quarter of fiscal 2026, gross profit was $3.5 million compared to $7.7 million in the prior comparable quarter. Gross margin was 17.1% compared to 18.5% for the second quarter of fiscal 2025. The decrease in gross margin was primarily due to changes in product mix with less higher margin products being sold during the three months ended December 31, 2025.

Total operating expenses were $10.3 million for the second fiscal quarter of 2026, compared to $15.1 million for the same period last year.

Net loss was $6.6 million or $0.12 per share for the fiscal second quarter of 2026, versus a net loss of $8.0 million, or $0.14 per share for the fiscal second quarter of 2025.

At December 31, 2025, Ispire held cash of $17.6 million and working capital of $3.5 million.

Conference Call

The Company will conduct a conference call at 8:00 am ET on Friday, February 6, 2026, to discuss the results, followed by a Q&A session.

To listen to the conference call, please dial in using the information below. When prompted upon dialing-in, please ask for the “Ispire Technology Call.”

Date: Friday, February 6, 2026
Time: 8:00 am ET
Dial-In Numbers: United States 877-451-6152 or International +1 201-389-0879

This conference call will be webcast live and can be accessed by all interested parties at https://viavid.webcasts.com/starthere.jsp?ei=1749224&tp_key=1ec45fe266.

Please access the link at least fifteen minutes prior to the start of the call to register, download, and install any necessary audio software.

A playback will be available until 11:59 pm ET on Friday, February 20, 2026. To listen, please dial 1-844-512-2921 or 1-412-317-6671. Use the passcode 13758138 to access the replay.

About Ispire Technology Inc.
Ispire is engaged in the research and development, design, commercialization, sales, marketing and distribution of branded e-cigarettes and cannabis vaping products. The Company’s operating subsidiaries own or license more than 400 patents worldwide. Ispire’s branded e-cigarette products are marketed under the Aspire name and are sold worldwide (except in the U.S., People’s Republic of China and Russia) primarily through its global distribution network. The Company also engages in original design manufacture (ODM) relationships with e-cigarette brands and retailers worldwide. The Company’s cannabis products are marketed under the Ispire brand name primarily on an ODM basis to other cannabis vapor companies. Ispire sells its cannabis vaping hardware in the US, Europe and South Africa and it recently commenced marketing activities and customer engagement in Canada and Latin America. For more information, visit www.ispiretechnology.com or follow Ispire on Instagram, LinkedIn, Twitter and YouTube.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (“Securities Act”) as well as Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended, that are intended to be covered by the safe harbor created by those sections. Forward-looking statements, which are based on certain assumptions and describe the Company’s future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “would,” “could,” “seek,” “intend,” “plan,” “goal,” “project,” “estimate,” “anticipate,” “strategy,” “future,” “likely” or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the Company’s strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Important factors that could cause the Company’s actual results and financial condition to differ materially from those indicated in the forward-looking statements. Such forward-looking statements include, but are not limited to, risks and uncertainties including those regarding: whether the Company may be successful in re-entering the U.S. ENDS market; the approval or rejection of any PMTA submitted by the Company; whether the Company will be successful in its plans to further expand into the African market; whether the Company’s joint venture with Touch Point Worldwide Inc. d/b/a/ Berify and Chemular Inc. (the “Joint Venture”) may be successful in achieving its goals as currently contemplated, with different terms, or at all; the Joint Venture’s ability to innovate in the e-cigarette technology space or develop age gating or age verification technologies for nicotine vaping devices; the Company’s ability to collect its accounts receivable in a timely manner; the Company’s business strategies; the ability of the Company to market to the Ispire ONE™; Ispire ONE™’s success in meeting its goals; the ability of its customers to derive the anticipated benefits of the Ispire ONE™ and the success of its products on the markets; the Ispire ONE™ proving to be safe; and the risk and uncertainties described in “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” “Cautionary Note on Forward-Looking Statements” and the additional risk described in Ispire’s Annual Report on Form 10-K for the year ended June 30, 2025 and any subsequent filings which Ispire makes with the SEC. You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements made in this press release relate only to events or information as of the date on which the statements are made in this press release. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events except as required by applicable law. You should read this press release with the understanding that our actual future results may be materially different from what we expect.

ISPIRE TECHNOLOGY INC. UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (In $USD, except share and per share data)
	December 31, 2025		June 30, 2025
Assets
Current assets:
Cash	$	17,565,334	$	24,351,765
Restricted cash		50,000		–
Accounts receivable, net		37,878,353		39,664,145
Inventories		5,037,414		6,647,970
Prepaid expenses and other current assets		3,120,978		2,244,505
Total current assets		63,652,079		72,908,385
Non-current assets:
Accounts receivable, net of current portion		–		7,367,158
Property, plant and equipment, net		2,599,861		2,952,800
Intangible assets, net		2,474,037		2,232,620
Right-of-use assets – operating leases		4,335,355		5,030,005
Other investment		2,000,000		2,000,000
Equity method investment		9,129,213		9,515,546
Other non-current assets		210,617		210,617
Total non-current assets		20,749,083		29,308,746
Total assets	$	84,401,162	$	102,217,131
Liabilities and stockholders’ equity
Current liabilities
Accounts payable	$	3,137,235	$	4,172,476
Accounts payable – related party		42,444,624		52,420,256
Contract liabilities		4,971,135		4,861,250
Accrued liabilities and other payables		6,818,397		8,099,991
Income tax payable		12,590		–
Borrowing – current portion		1,146,766		1,146,766
Operating lease liabilities – current portion		1,659,698		1,838,815
Total current liabilities		60,190,445		72,539,554

Non-current liabilities:
Amount due to a related party		29,000,000		25,000,000
Borrowing – net of current portion		231,978		805,361
Operating lease liabilities – net of current portion		2,642,156		3,267,522
Total non-current liabilities		31,874,134		29,072,883
Total liabilities		92,064,579		101,612,437

Commitments and contingencies

Stockholders’ (deficit)/equity:
Common stock, par value $0.0001 per share; 140,000,000 shares authorized; 57,289,864 and 57,193,734 shares issued and outstanding as of December 31, 2025 and June 30, 2025		5,729		5,719
Treasury stock, at cost		(105,489)		(60,488)
Additional paid-in capital		50,593,580		48,833,601
Accumulated deficit		(57,927,041)		(48,065,267)
Accumulated other comprehensive loss		(230,196)		(108,871)
Total stockholders’ (deficit)/equity		(7,663,417)		604,694
Total liabilities and stockholders’ (deficit)/equity	$	84,401,162	$	102,217,131

For more information, kindly contact:

IR Contacts:

KCSA Strategic Communications
Phil Carlson
212-896-1233
ispire@kcsa.com

PR Contact:
Ellen Mellody
570-209-2947
EMellody@kcsa.com

February 6, 2026

Ispire-Backed IKE Tech Invited to Participate in FDA Roundtable on PMTA Submissions

Invitation-Only Forum Underscores FDA Recognition of IKE Tech as a Key Stakeholder and Highlights the Strategic Role of Age-Gating Technology in the Future of ENDS Regulation and Compliance

Los Angeles, February 4, 2026 – Ispire Technology Inc. (“Ispire” or the “Company”) (NASDAQ: ISPR),

a trailblazer in vaping technology and precision dosing, announced that IKE Tech LLC (“IKE Tech” or “IKE”), a joint venture that includes Ispire as a founding partner, has been invited by the U.S. Food and Drug Administration (FDA) to participate in its Roundtable Discussion with Small ENDS Manufacturers on Premarket Tobacco Product Application (PMTA) Submissions.

The invitation-only roundtable, taking place February 10, is the first FDA forum of its kind focused on gathering direct feedback from select electronic nicotine delivery system (ENDS) manufacturers on the PMTA process. Participation is limited to 30 companies nationwide, underscoring FDA recognition of IKE Tech as an important stakeholder in the evolving regulatory framework for ENDS products.

IKE is set to participate on the Manufacturing Controls panel — one of five FDA-led panel discussions designed to examine real-world challenges, best practices and opportunities for improving the PMTA process.

“This invitation reflects growing recognition by regulators that technology, particularly point-of-use age-gating, is a critical component of a responsible ENDS ecosystem,” said Michael Wang, Co-CEO of Ispire. “This is a significant opportunity to contribute constructively to a dialogue that can improve regulatory clarity while advancing public health objectives. The FDA’s engagement reinforces that age-gating is no longer a peripheral concept — it is central to the future of regulation. We look forward to sharing how technical controls can offer a more effective pathway for adult products while ensuring the highest standards of youth protection.”

IKE is developing a blockchain-enabled, Bluetooth-based age-gating component designed to verify legal-age access at the point of use, rather than solely at retail. The technology recently became the subject of the first-ever component PMTA submission for an interoperable age-verification system, positioning it as a potential enabling technology for next-generation regulatory compliance.

Wang added: “Our strategic investment in IKE Tech positions Ispire at the center of regulatory dialogue as the FDA evaluates how innovation can strengthen compliance, protect youth and support lawful market pathways for adult products. By aligning commercial participation with strategic integration, we are advancing our long-term commitment to safety-focused innovation and regulatory readiness”

The FDA roundtable is intended to provide manufacturers with an opportunity to share firsthand experience and perspectives on PMTA submissions, including scientific, manufacturing and operational considerations. Feedback from the session is expected to inform future FDA guidance and potential refinements to the PMTA review process.

About IKE Tech LLC
IKE Tech LLC is a joint venture comprised of Ispire Technology Inc., Touch Point Worldwide Inc. d/b/a Berify, and Chemular Inc. Founded in 2024, IKE Tech is building the identity layer for the physical world. With patented technologies spanning blockchain authentication, secure BLE communication, and AI-enhanced access control, IKE powers secure, user-centric device interactions across regulated and high-risk sectors.

IKE’s System-on-a-Chip allows manufacturers to embed customizable, interoperable access controls into vapor devices — ensuring authorized adult use and preventing youth access through real-time mobile and biometric authentication. Visit www.iketech.com.

About Ispire Technology Inc.
Ispire is engaged in the research and development, design, commercialization, sales, marketing and distribution of branded e-cigarettes and cannabis vaping products. The Company’s operating subsidiaries own or license more than 400 patents worldwide. Ispire’s branded e-cigarette products are marketed under the Aspire name and are sold worldwide (except in the U.S., People’s Republic of China and Russia) primarily through its global distribution network. The Company also engages in original design manufacture (ODM) relationships with e-cigarette brands and retailers worldwide. The Company’s cannabis products are marketed under the Ispire brand name primarily on an ODM basis to other cannabis vapor companies. Ispire sells its cannabis vaping hardware in the US, Europe and South Africa and it recently commenced marketing activities and customer engagement in Canada and Latin America. For more information, visit www.ispiretechnology.com or follow Ispire on Instagram, LinkedIn, Twitter and YouTube.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (“Securities Act”) as well as Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended, that are intended to be covered by the safe harbor created by those sections. Forward-looking statements, which are based on certain assumptions and describe the Company’s future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “would,” “could,” “seek,” “intend,” “plan,” “goal,” “project,” “estimate,” “anticipate,” “strategy,” “future,” “likely” or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the Company’s strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Important factors that could cause the Company’s actual results and financial condition to differ materially from those indicated in the forward-looking statements. Such forward-looking statements include, but are not limited to, risks and uncertainties including those regarding: whether the Company may be successful in re-entering the U.S. ENDS market; the approval or rejection of any PMTA submitted by the Company; whether the Company will be successful in its plans to further expand into the African market; whether the Company’s joint venture with Touch Point Worldwide Inc. d/b/a/ Berify and Chemular Inc. (the “Joint Venture”) may be successful in achieving its goals as currently contemplated, with different terms, or at all; the Joint Venture’s ability to innovate in the e-cigarette technology space or develop age gating or age verification technologies for nicotine vaping devices; the Company’s ability to collect its accounts receivable in a timely manner; the Company’s business strategies; the ability of the Company to market to the Ispire ONE™; Ispire ONE™’s success in meeting its goals; the ability of its customers to derive the anticipated benefits of the Ispire ONE™ and the success of its products on the markets; the Ispire ONE™ proving to be safe; and the risk and uncertainties described in “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” “Cautionary Note on Forward-Looking Statements” and the additional risk described in Ispire’s Annual Report on Form 10-K for the year ended June 30, 2025 and any subsequent filings which Ispire makes with the SEC. You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements made in this press release relate only to events or information as of the date on which the statements are made in this press release. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events except as required by applicable law. You should read this press release with the understanding that our actual future results may be materially different from what we expect.

IR Contact:
Phil Carlson
+1-212-896-1233
ispire@kcsa.com

PR Contact:
Ellen Mellody
+1-570-209-2947
ispire@kcsa.com

February 4, 2026

Ispire Technology Inc. Schedules Fiscal Second Quarter 2026 Earnings Conference Call

Los Angeles, February 3, 2026 – Ispire Technology Inc. (“Ispire” or the “Company”) (NASDAQ: ISPR), a trailblazer in vaping technology and precision dosing, announced today that it will host its earnings conference call at 8:00 am ET on Friday, February 6, 2026, to discuss the Company’s financial results for its fiscal second quarter ended December 31, 2025.

To listen to the conference call, please dial in using the information below. When prompted upon dialing-in, please ask for the “Ispire Technology Call.”

Date: Friday, February 6, 2026
Time: 8:00 am ET
Dial-In Numbers: United States 877-451-6152 or International +1 201-389-0879

This conference call will be webcast live and can be accessed by all interested parties at https://viavid.webcasts.com/starthere.jsp?ei=1749224&tp_key=1ec45fe266.

Please access the link at least fifteen minutes prior to the start of the call to register, download, and install any necessary audio software.

A playback will be available until 11:59 pm ET on Friday, February 20, 2026. To listen, please dial 1-844-512-2921 or 1-412-317-6671. Use the passcode 13758138 to access the replay.

About Ispire Technology Inc.
Ispire is engaged in the research and development, design, commercialization, sales, marketing and distribution of branded e-cigarettes and cannabis vaping products. The Company’s operating subsidiaries own or license more than 400 patents worldwide. Ispire’s branded e-cigarette products are marketed under the Aspire name and are sold worldwide (except in the U.S., People’s Republic of China and Russia) primarily through its global distribution network. The Company also engages in original design manufacture (ODM) relationships with e-cigarette brands and retailers worldwide. The Company’s cannabis products are marketed under the Ispire brand name primarily on an ODM basis to other cannabis vapor companies. Ispire sells its cannabis vaping hardware in the US, Europe and South Africa and it recently commenced marketing activities and customer engagement in Canada and Latin America. For more information, visit www.ispiretechnology.com or follow Ispire on Instagram, LinkedIn, Twitter and YouTube.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (“Securities Act”) as well as Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended, that are intended to be covered by the safe harbor created by those sections. Forward-looking statements, which are based on certain assumptions and describe the Company’s future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “would,” “could,” “seek,” “intend,” “plan,” “goal,” “project,” “estimate,” “anticipate,” “strategy,” “future,” “likely” or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the Company’s strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Important factors that could cause the Company’s actual results and financial condition to differ materially from those indicated in the forward-looking statements. Such forward-looking statements include, but are not limited to, risks and uncertainties including those regarding: the Company meeting its investment target in Malaysia as currently planned, to a lesser degree, or at all; the Company’s continued compliance with applicable laws and regulations in the jurisdictions in which it operates; the approval or rejection of any PMTA submitted by the Company; whether the Company’s joint venture with Touch Point Worldwide Inc. d/b/a/ Berify and Chemular Inc. (the “Joint Venture”) may be successful in achieving its goals regarding age-gating technology, or otherwise, as currently contemplated, with different terms, or at all; the Joint Venture’s ability to innovate in the e-cigarette technology space or develop age gating or age verification technologies for nicotine vaping devices; the Company’s business strategies; and the risk and uncertainties described in “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” “Cautionary Note on Forward-Looking Statements” and the additional risk described in Ispire’s Annual Report on Form 10-K for the year ended June 30, 2025 and any subsequent filings which Ispire makes with the SEC, including the Ispire’s Quarterly Report on Form 10-Q for the period ended March 31, 2025. You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements made in this press release relate only to events or information as of the date on which the statements are made in this press release. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events except as required by applicable law. You should read this press release with the understanding that our actual future results may be materially different from what we expect.

IR Contact:
KCSA Strategic Communications
Phil Carlson
212.896.1233
ispire@kcsa.com

PR Contact:
Ellen Mellody
570.209.2947
ispire@kcsa.com

February 3, 2026

Ispire Technology Inc. Reports Financial Results for the Fiscal Year 2025

Cost cutting measures instituted in Fiscal 2025 helped cut total operating expenses by approximately 39% to $7.8 Million year-over-year

Net Accounts Receivable Reduced approximately 29% from $62.4 Million to $44.5 Million Year-Over-Year

Cash and Cash Equivalents of $22.7 Million at September 30, 2025

Los Angeles, November 6, 2025 – Ispire Technology Inc. (NASDAQ: ISPR) (“Ispire,” the “Company,” “we,” “us,” or “our”), an innovator in vaping technology and precision dosing, today reported financial results for the first quarter of fiscal 2026, for the three months ended September 30, 2025.

Fiscal First Quarter 2026 Financial Results

Revenue of $30.4 million versus $39.3 million for the first quarter of fiscal 2025.
Gross profit of $5.1 million compared to $7.7 million for the first quarter of fiscal 2025.
Gross margin of 17.0% compared to 19.5% for the first quarter of fiscal 2025.
Total operating expenses of $7.8 million compared to $12.9 million for the first quarter of fiscal 2025.
Net loss of $3.3 million, compared to net loss of $5.6 million in the first quarter of fiscal 2025.

“Our first fiscal quarter 2026 results demonstrate the steps we instituted in fiscal 2025 to strengthen our financial foundation and position Ispire for sustainable, profitable growth are taking effect,” commented Michael Wang, Co-Chief Executive Officer of Ispire. “We made a deliberate decision to focus on quality customers over volume, and while revenue of $30.4 million reflects this strategic shift, the operational improvements are substantial. Our total operating expenses decreased significantly to $7.8 million compared to $12.9 million in the same period last year, a reduction of nearly 39% while our net accounts receivable declined approximately 29% from $62.4 million as of September 30, 2024 to $44.5 million as of September 30, 2025. This improvement was a direct result of our focus on aggressive cost controls, disciplined expense management, and higher quality customers, while bringing our non-GAAP EBITDA to $0.6 million for the quarter ended September 30, 2025. We expect this trend to continue through fiscal 2026.”

“From an operations standpoint, our IKE Tech joint venture is gaining meaningful traction globally, working with regulators in Europe, Southeast Asia, and the Middle East to adopt age-gating technology as a mandatory standard. We are in deep discussions with numerous large and medium-sized nicotine companies regarding our innovative G-Mesh technology solutions for their next-generation vaping devices, as we aim to secure licensure and/or partnership agreements in the coming months. Lastly, we remain excited about the build-out of our Malaysian manufacturing facility as we look to ramp up production in fiscal 2026,” Mr. Wang concluded.

Jay Yu, Chief Financial Officer of Ispire, said, “This quarter represents a significant milestone in our financial transformation. The substantial reduction in operating expenses from $12.9 million to $7.8 million year-over-year demonstrates that our cost optimization initiatives are delivering significant results. We also reduced net accounts receivable to $44.5 million as of Septmber 30, 2025 versus nearly $62.4 million as of September 30, 2024, as we continue to focus on improving working capital and pursuing higher-quality customers. We remain committed to generating shareholder value through sustainable cash flow generation and continued balance sheet strengthening.”

Financial Results for the Fiscal First Quarter Ended September 30, 2025

Ispire reported revenue of $30.4 million for the fiscal first quarter ended September 30, 2025, versus $39.3 million for the prior comparable period, a decrease of 22.8%. The decrease in revenue is the combined effect of decreases in product sales in the United States as well as a decrease in vaping product sales across Asia Pacific, Europe and South Africa.

For the first quarter of fiscal 2026, gross profit was $5.1 million compared to $7.7 million in the year-ago period. Gross margin decreased to 17.0% compared to 19.5% for the first quarter of fiscal 2025. The decrease in gross margin was primarily due to changes in product mix with less higher margin products being sold during the three months ended September 30, 2025.

Total operating expenses were $7.8 million for the first fiscal quarter of 2026, compared to $12.9 million for the same period last year.

Net loss was $3.3 million or $0.06 per share for the fiscal first quarter of 2026, versus a net loss of $5.6 million, or $0.10 per share for the fiscal first quarter of 2025.

At September 30, 2025, Ispire held cash and cash equivalents of $22.7 million and working capital of $9.3 million.

Non-GAAP First Quarter Net Income/loss
	Three Months Ended
	September 30,
	2025		2024

NET LOSS		(3,258,863)		(5,595,016)

Add Credit Loss Expenses		1,764,252		3,102,081
Add Income Tax		486,069		456,753
Add Stock based compensation		938,148		2,007,588
Add Inventory Impairment		423,457		73,692
Add Depreciation and Amortization		253,410		204,807
Add Debt issuance cost amortization		32,312		–
NON-GAAP EBITDA		638,785		249,905

Management’s Explanation of Non-GAAP Financial Measures

The Company believes that presenting Non-GAAP financial information provides meaningful supplemental data that assists investors in understanding its operating results. The adjustments to GAAP net loss primarily include non-cash expenses or non-recurring items that management believes are not indicative of ongoing performance. The following non-GAAP financial measures should be considered in addition to, and not as a substitute for, the most directly comparable GAAP financial measures. We believe these non-GAAP financial measures, when used in conjunction with their most directly comparable GAAP financial measures, net income (loss), provide meaningful supplemental information to both management and investors, facilitating the evaluation of performance across reporting periods, identify trends affecting our business, and project future performance. These non-GAAP financial measures may be different from non-GAAP financial measures used by other companies. Specifically, the adjustments include:

Credit loss expenses, a non-cash item, which reflect provisions recorded under the Company’s CECL methodology and may vary significantly as the Company develops additional historical experience.
Income tax expense, which can fluctuate based on jurisdictional mix and timing of taxable income.
Stock-based compensation, a non-cash expense related to equity awards.
Inventory impairment, representing non-cash write-downs of certain slow-moving or obsolete inventory.
Depreciation, which is a non-cash charge related to fixed assets.
Debt issuance cost amortization, which is a non-cash charge related to the loan payable.

Conference Call

The Company will conduct a conference call at 8:00 am Eastern Time on Thursday, November 6, 2025, to discuss the results, followed by a Q&A session.

To listen to the conference call, please dial in using the information below. When prompted upon dialing-in, please ask for the “Ispire Technology Call.”

Date: Thursday, November 6, 2025
Time: 8:00am ET
Dial-In Numbers: North America 844-826-3033 or International +1 412-317-5185

This conference call will be webcast live and can be accessed by all interested parties at https://viavid.webcasts.com/starthere.jsp?ei=1738889&tp_key=82f919c8ba.

Please access the link at least fifteen minutes prior to the start of the call to register, download, and install any necessary audio software.

A playback will be available until 12:00 midnight Eastern Time on Thursday, November 20, 2025. To listen, please dial 844-512-2921 or +1 412-317-6671. Use the passcode 10203874 to access the replay.

About Ispire Technology Inc.
Ispire is engaged in the research and development, design, commercialization, sales, marketing and distribution of branded e-cigarettes and cannabis vaping products. The Company’s operating subsidiaries own or license more than 400 patents worldwide. Ispire’s branded e-cigarette products are marketed under the Aspire name and are sold worldwide (except in the U.S., People’s Republic of China and Russia) primarily through its global distribution network. The Company also engages in original design manufacture (ODM) relationships with e-cigarette brands and retailers worldwide. The Company’s cannabis products are marketed under the Ispire brand name primarily on an ODM basis to other cannabis vapor companies. Ispire sells its cannabis vaping hardware in the US, Europe and South Africa and it recently commenced marketing activities and customer engagement in Canada and Latin America. For more information, visit www.ispiretechnology.com or follow Ispire on Instagram, LinkedIn, Twitter and YouTube.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (“Securities Act”) as well as Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended, that are intended to be covered by the safe harbor created by those sections. Forward-looking statements, which are based on certain assumptions and describe the Company’s future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “would,” “could,” “seek,” “intend,” “plan,” “goal,” “project,” “estimate,” “anticipate,” “strategy,” “future,” “likely” or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the Company’s strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Important factors that could cause the Company’s actual results and financial condition to differ materially from those indicated in the forward-looking statements. Such forward-looking statements include, but are not limited to, risks and uncertainties including those regarding: whether the Company may be successful in re-entering the U.S. ENDS market; the approval or rejection of any PMTA submitted by the Company; whether the Company will be successful in its plans to further expand into the African market; whether the Company’s joint venture with Touch Point Worldwide Inc. d/b/a/ Berify and Chemular Inc. (the “Joint Venture”) may be successful in achieving its goals as currently contemplated, with different terms, or at all; the Joint Venture’s ability to innovate in the e-cigarette technology space or develop age gating or age verification technologies for nicotine vaping devices; the Company’s ability to collect its accounts receivable in a timely manner; the Company’s business strategies; the ability of the Company to market to the Ispire ONE™; Ispire ONE™’s success in meeting its goals; the ability of its customers to derive the anticipated benefits of the Ispire ONE™ and the success of its products on the markets; the Ispire ONE™ proving to be safe; and the risk and uncertainties described in “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” “Cautionary Note on Forward-Looking Statements” and the additional risk described in Ispire’s Annual Report on Form 10-K for the year ended June 30, 2025 and any subsequent filings which Ispire makes with the SEC. You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements made in this press release relate only to events or information as of the date on which the statements are made in this press release. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events except as required by applicable law. You should read this press release with the understanding that our actual future results may be materially different from what we expect.

ISPIRE TECHNOLOGY INC.
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
(In $USD, except share and per share data)

	September 30, 2025		June 30, 2025
Assets
Current assets:
Cash	$	22,659,118	$	24,351,765
Restricted cash		50,000		–
Accounts receivable, net		44,522,796		39,664,145
Inventories, net		6,162,118		6,647,970
Prepaid expenses and other current assets		1,733,658		2,244,505
Total current assets		75,127,690		72,908,385
Non-current assets:
Accounts receivable – non current		–		7,367,158
Property, plant and equipment, net		2,731,346		2,952,800
Intangible assets, net		2,340,700		2,232,620
Right-of-use assets – operating leases		4,719,751		5,030,005
Other investment		2,000,000		2,000,000
Equity method investment		9,316,267		9,515,546
Other non-current assets		210,617		210,617
Total non-current assets		21,318,681		29,308,746
Total assets	$	96,446,371	$	102,217,131
Liabilities and stockholders’ equity
Current liabilities
Accounts payable	$	4,654,008	$	4,172,476
Accounts payable – related party		47,442,029		52,420,256
Contract liabilities		2,962,299		4,861,250
Accrued liabilities and other payables		7,575,391		8,099,991
Income tax payable		281,856		–
Borrowing – current portion		1,146,766		1,146,766
Operating lease liabilities – current portion		1,750,411		1,838,815
Total current liabilities		65,812,760		72,539,554

Non-current liabilities:
Amount due to a related party		29,000,000		25,000,000
Borrowing – net of current portion		518,669		805,361
Operating lease liabilities – net of current portion		2,883,856		3,267,522
Total non-current liabilities		32,402,525		29,072,883
Total liabilities		98,215,285		101,612,437

Commitments and contingencies

Stockholders’ equity:
Common stock, par value $0.0001 per share; 140,000,000 shares authorized; 57,289,864 and 57,193,734 shares issued and outstanding as of September 30, 2025 and June 30, 2025		5,729		5,719
Treasury stock, at cost		(105,489)		(60,488)
Additional paid-in capital		49,771,739		48,833,601
Accumulated deficit		(51,324,130)		(48,065,267)
Accumulated other comprehensive loss		(116,763)		(108,871)
Total stockholders’ (deficit)/equity		(1,768,914)		604,694
Total liabilities and stockholders’ equity	$	96,446,371	$	102,217,131

ISPIRE TECHNOLOGY INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND
COMPREHENSIVE LOSS
(In $USD, except share and per share data)

	Three Months Ended September 30,
	2025		2024

Revenue	$	30,350,884	$	39,338,313
Cost of revenue		25,204,112		31,663,935
Gross profit		5,146,772		7,674,378
Operating expenses:
Sales and marketing expenses		1,564,844		2,992,247
Credit loss expenses		1,764,252		3,102,081
General and administrative expenses		4,512,985		6,842,919
Total operating expenses		7,842,081		12,937,247
Loss from operations		(2,695,309)		(5,262,869)
Other (expense) income, net:
Interest income		95,472		86
Interest expense		(112,176)		(11,464)
Exchange gain, net		9,802		117,585
Other (expense) income, net		(70,583)		18,399
Total other (expense) income, net		(77,485)		124,606
Loss before income taxes		(2,772,794)		(5,138,263)
Income taxes		(486,069)		(456,753)
Net loss	$	(3,258,863)	$	(5,595,016)
Other comprehensive loss
Foreign currency translation adjustments		(7,892)		(154,937)
Comprehensive loss		(3,266,755)		(5,749,953)
Net loss per share
Basic and diluted	$	(0.06)	$	(0.10)
Weighted average shares outstanding:
Basic and diluted		57,273,184		56,601,320

For more information, kindly contact:

IR Contacts:

KCSA Strategic Communications
Phil Carlson
212-896-1233
ispire@kcsa.com

PR Contact:
Ellen Mellody
570-209-2947
EMellody@kcsa.com

November 6, 2025

Ispire Technology Inc. Schedules Fiscal First Quarter 2026 Earnings Conference Call

Los Angeles, November 4, 2025 – Ispire Technology Inc. (“Ispire” or the “Company”) (NASDAQ: ISPR), a trailblazer in vaping technology and precision dosing, announced today that it will host its earnings conference call at 8:00 am ET on Thursday, November 6, 2025, to discuss the Company’s financial results for its fiscal first quarter ended September 30, 2025.

To listen to the conference call, please dial in using the information below. When prompted upon dialing-in, please ask for the “Ispire Technology Call.”

Date: Thursday, November 6, 2025
Time: 8:00 am ET
Dial-In Numbers: United States 844-826-3033 or International +1 412-317-5185

This conference call will be webcast live and can be accessed by all interested parties at https://viavid.webcasts.com/starthere.jsp?ei=1738889&tp_key=82f919c8ba.

Please access the link at least fifteen minutes prior to the start of the call to register, download, and install any necessary audio software.

A playback will be available until 12:00 midnight Eastern Time on Thursday, November 20, 2025. To listen, please dial 844-512-2921 or +1 412-317-6671. Use the passcode 10203874 to access the replay.

About Ispire Technology Inc.
Ispire is engaged in the research and development, design, commercialization, sales, marketing and distribution of branded e-cigarettes and cannabis vaping products. The Company’s operating subsidiaries own or license more than 400 patents worldwide. Ispire’s branded e-cigarette products are marketed under the Aspire name and are sold worldwide (except in the U.S., People’s Republic of China and Russia) primarily through its global distribution network. The Company also engages in original design manufacture (ODM) relationships with e-cigarette brands and retailers worldwide. The Company’s cannabis products are marketed under the Ispire brand name primarily on an ODM basis to other cannabis vapor companies. Ispire sells its cannabis vaping hardware in the US, Europe and South Africa and it recently commenced marketing activities and customer engagement in Canada and Latin America. For more information, visit www.ispiretechnology.com or follow Ispire on Instagram, LinkedIn, Twitter and YouTube.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (“Securities Act”) as well as Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended, that are intended to be covered by the safe harbor created by those sections. Forward-looking statements, which are based on certain assumptions and describe the Company’s future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “would,” “could,” “seek,” “intend,” “plan,” “goal,” “project,” “estimate,” “anticipate,” “strategy,” “future,” “likely” or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the Company’s strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Important factors that could cause the Company’s actual results and financial condition to differ materially from those indicated in the forward-looking statements. Such forward-looking statements include, but are not limited to, risks and uncertainties including those regarding: the Company meeting its investment target in Malaysia as currently planned, to a lesser degree, or at all; the Company’s continued compliance with applicable laws and regulations in the jurisdictions in which it operates; the approval or rejection of any PMTA submitted by the Company; whether the Company’s joint venture with Touch Point Worldwide Inc. d/b/a/ Berify and Chemular Inc. (the “Joint Venture”) may be successful in achieving its goals regarding age-gating technology, or otherwise, as currently contemplated, with different terms, or at all; the Joint Venture’s ability to innovate in the e-cigarette technology space or develop age gating or age verification technologies for nicotine vaping devices; the Company’s business strategies; and the risk and uncertainties described in “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” “Cautionary Note on Forward-Looking Statements” and the additional risk described in Ispire’s Annual Report on Form 10-K for the year ended June 30, 2025 and any subsequent filings which Ispire makes with the SEC, including the Ispire’s Quarterly Report on Form 10-Q for the period ended March 31, 2025. You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements made in this press release relate only to events or information as of the date on which the statements are made in this press release. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events except as required by applicable law. You should read this press release with the understanding that our actual future results may be materially different from what we expect.

IR Contact:
KCSA Strategic Communications
Phil Carlson
212.896.1233
ispire@kcsa.com

PR Contact:
Ellen Mellody
570.209.2947
ispire@kcsa.com

November 4, 2025

Author: webdev

FDA establishes first-ever framework for flavored ENDS, recognizing device level age verification as a regulatory requirement

Economic Opportunity and Market Impact

About IKE Tech LLC

About Ispire Technology Inc.

Forward Looking Statements